30.49 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||30.53 x 800|
|Ask||30.58 x 2200|
|Day's Range||30.48 - 30.95|
|52 Week Range||22.57 - 33.92|
|Beta (5Y Monthly)||0.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.57|
Mike Carrel, CEO of AtriCure Inc., said the recent acquisition of a California firm that also makes devices to treat heart ailments could pay off not only for the Mason-based company and its shareholders but also for patients with atrial fibrillation.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prange and Daniel Florin have been named to its Board of Directors. Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein (HSIC) and a member of the Executive Committee.
AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York City.
AtriCure (ATRC) delivered earnings and revenue surprises of -17.86% and 1.90%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
MASON, Ohio-- -- Worldwide revenue of $56.6 million – an increase of 13.4% year over year U.S. revenue of $46.1 million – an increase of 16.0% year over year International revenue of $10.5 million – an increase of 3.1% year over year AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced third quarter 2019 financial results. ...
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that the company will be participating in upcoming investor conferences.
DAFNA Capital Management was founded in 1999 by Dr. Nathan Fischel, who is the fund’s CEO. Dr. Fischel is Pediatric Hematologist-Oncologist with a long career in medicine. He graduated from Technion School of Medicine in Israel and completed his residency at the Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston. He continued his […]
It hasn't been the best quarter for AtriCure, Inc. (NASDAQ:ATRC) shareholders, since the share price has fallen 20% in...
AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019.
When AtriCure, Inc. (NASDAQ:ATRC) released its most recent earnings update (30 June 2019), I compared it against two...